Oncology
Global

Oncology Experts

Mike Gallatin


Oncology
OncoResponse
United States of America

Biography

 Mike brings over 35 years of experience as a scientist and executive to the OncoResponse Scientific Advisory Board. He is a member of Frazier Healthcare Partners' Life Sciences team, has co-founded Calistoga (acquired by Gilead) and Stromedix (acquired by Biogen Idec) and served as President of Calistoga, which was the first company to demonstrate the clinical benefit of an isoform selective PI3K (idelalisib) inhibitor in hematologic malignancies. That drug, under the brand name Zydelig, received approvals from both the FDA and EMA in 2014 to treat chronic lymphocytic leukemia and follicular lymphoma. Mike was one of the founding scientists at ICOS Corporation, where he served as VP and Scientific Director. Mike's responsibilities at ICOS included discovery, preclinical research, medicinal chemistry, and process chemistry groups including those that helped generate and support the worldwide registration and launch of Cialis. Earlier, Mike developed expertise in the fields of immunology/inflammation and oncology while on the faculty at the Fred Hutchinson Cancer Center. Mike has also been a member of the Scientific Advisory Boards of the Keystone Symposia, Caprion, and the University of Texas Department of Chemistry.

Research Interest

 Oncology

Global Experts from United States of America

Global Experts in Subject